TRI Portfolio
Adamas Pharmaceuticals, Inc. (formerly NeuroMolecular Pharmaceuticals, Inc.) is a specialty pharmaceutical company focused on the development and commercialization of improved combination therapeutics to treat important healthcare problems. The Company's initial focus is on novel therapeutics for neurological disorders.
CellCentric, Ltd. has established a network of exclusive relationships with more than 20 of the world's leading laboratories working in epigenetics. The company continues to build and manage a portfolio of novel targets, screens and hit compounds important in the modulation of epigenetic phenomena, preparing them for full scale pharmaceutical development.
Curidium Medica plc (CUR: LSE) specializes in the development of personalized medicines by applying its proprietary HomoMatrixTM technology to stratify patient populations, develop targeted medicines and identify companion diagnostics to treat patients with central nervous system diseases more effectively. Curidium is working with Takeda on novel approaches to the treatment of major depressive disorders
Envoy Therapeutics' mission is to discover new drugs with superior clinical utility using its novel bacTRAPİ technology. bacTRAP enables the identification of proteins that are produced in vivo by specific cell types without requiring the isolation of those cells. The technology is especially powerful in tissues of the brain where many hundreds of cell types are intermingled. For the first time, Envoy enables therapeutic modulation of the activity of specific a cell type by allowing profiling of proteins that are uniquely expressed by that cell type.
Lectus Therapeutics Ltd. is a UK biopharmaceutical company with an innovative, proprietary functional proteomics screening platform (LEPTICS™), enabling the discovery and development of novel, small molecule modulators of ion channels.
Patrys Ltd. is an innovative new biotechnology company pioneering the discovery and development of human IgM antibodies for the treatment of a variety of cancers. Patrys discovers potential human antibodies through its proprietary hybridoma technology.
Symphogen A/S is an innovative Danish biotechnology company pioneering the development of recombinant human polyclonal antibodies for the treatment and prevention of human diseases including inflammatory diseases and cancer. Symphogen's therapeutic antibodies - Symphobodies - mimic the diversity, affinity, and specificity of the human immune response and are therefore expected to offer advantages over current immunoglobulin and monoclonal antibody therapies.
Xenon Pharmaceuticals Inc. is a leading Canadian biopharmaceutical company using clinical genetic approaches to identify novel targets for a wide range of significant human diseases. By isolating the key genes underlying rare genetic disorders, the company has successfully identified drug targets for several common complex diseases. TRI's strategic investment will support efforts to find novel targets that potentially will lead to the development of innovative new treatments for atherosclerosis.
Portfolio Exits
Receptor Biologix Inc. acquired by Symphogen A/B, December 2008
Serenex acquired by Pfizer, April 2008